A phase II proof-of-concept study of PST-611 in geographic atrophy (GA)/dry age-related macular degeneration (AMD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Nov 2024 According to a PulseSight Therapeutics media release, the company plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its drug candidate PST-611 by the end 2027.
11 Oct 2024 New trial record
07 Oct 2024 According to a PulseSight Therapeutics media release, company is planning to submit a phase I clinical trial authorization (CTA) by end October, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety by end 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com